Melbourne Laboratories Announces Senior Positions
Robert W. Pollock Named President
MOUNTAIN VIEW, Calif., Oct. 14, 2014 /PRNewswire/ -- Melbourne Laboratories™ announced today the appointment of Robert W. Pollock as the Company's founding President and Chief Scientific Officer. Pollock joins Melbourne from Lachman Consulting Services, where he had a distinguished 20-year career working with industry to address a myriad of regulatory, compliance and development issues. Prior to Lachman Pollock was with the United States Public Health Service and spent his last 10 years with the FDA'S Generic Drug Program, retiring from PHS as the Acting Deputy Director in FDA's Office of Generic Drugs. Pollock will continue as a senior advisor to Lachman and will maintain his seat on the Lachman Board of Directors. "I am excited about the prospects for Melbourne and my role in making it a success," Pollock said.
Melbourne Laboratories, a newly formed drug development firm, has commenced development of products in a variety of therapeutic areas. "Melbourne products will offer clinicians and patients important alternatives to existing forms of previously-approved chemical entities, as well as provide novel products that address the special needs of patients with rare or orphan diseases," Pollock said.
Separately, Melbourne Laboratories also announced that Ken Greathouse and Brian Smith will join Pollock as the initial founding members of Melbourne, with Greathouse serving as CEO role and Smith assuming the role of COO. "Brian and I are thrilled to have Bob join the founding team at Melbourne," Greathouse said. "Bob brings a wealth of knowledge and experience that will be instrumental to identifying and advancing the development candidates at Melbourne." Pollock added, "This opportunity is something the three of us have talked about for quite a while, and now it has come to fruition."
Melbourne's business plan includes the internal identification and development of appropriate product candidates as well as external partnership arrangements where the experience of the Melbourne team may add significant value. Companies interested in exploring potential partnership opportunities should visit the Melbourne website at www.melbournelaboratories.com for contact information. Pollock can be reached at [email protected].
About Melbourne Laboratories
Advancing novel therapies from promising ideas to marketable products
Melbourne Laboratories LLC is a newly-created company specializing in the development of novel pharmaceutical products across a wide spectrum of therapeutic classes. The three founding members of Melbourne have deep experience in a wide variety of practice areas, including FDA regulatory requirements, clinical development, manufacturing, API sourcing and commercialization.
Melbourne is currently advancing projects that will be available for licensing over the next few years. The Company is also interested in partnering with individuals and companies with projects that could benefit from Melbourne's expertise.
Contact Melbourne Laboratories at [email protected].
Logo - http://photos.prnewswire.com/prnh/20141014/152109LOGO
SOURCE Melbourne Laboratories
Share this article